LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.
Journal Information
Full Title: Clin Transl Sci
Abbreviation: Clin Transl Sci
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST STATEMENT We disclose that all authors associated with Novartis Biomedical Research or Novartis Pharma AG are current or former employees of and hold company stocks or stock options with Novartis Pharma AG, the company that is developing LYS006 as pharmacological treatment in inflammatory diseases. All other authors declared no competing interests for this work."
Funding Disclosure
Evidence found in paper:
"FUNDING INFORMATION The study was funded by Novartis Pharma AG, Switzerland."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025